Literature DB >> 28660502

Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs.

Shujian Xu1,2, Cui Zhao3, Zhongming Jia2, Xilong Wang2, Yong Han2, Zhenlin Yang4.   

Abstract

PURPOSE: Breast cancer is the most common invasive type of cancer among women. Role of different microRNAs (miRNAs) and poly(ADP-ribose) polymerases (PARPs) in breast cancer has been well established. This study aimed to explore the effects of miR-891b on sensitizing breast cancer cells to alkylating chemotherapeutic drugs through PARPs.
METHODS: The expression of miR-891b and PARP1 in human breast cancer cells HCC1806 was overexpressed by transfection with their mimics or expressing vector. Then, the transfected cells were exposed to 40 µM N-methyl-N-nitro-N-nitrosoguanidine (MNNG) for 1 h. The correlation between miR-891b and PARP1 was detected by RT-qPCR, western blot, and dual-luciferase reporter assay. Besides, MTT assay and Annexin V assay were done to measure cell proliferation and apoptosis, respectively.
RESULTS: PARP1 was a target of miR-891b, and it was negatively regulated by miR-891b. MiR-891b increased the sensitivity of the HCC1806 cells to the cytotoxic effects of MNNG through suppressing cell proliferation and increasing the percentage of apoptotic cells. Restoration of PARP1 activity in the HCC1806 cells led to loss of miR-891b mediated sensitivity of the HCC1806 cells to MNNG.
CONCLUSION: MiR-891b increases the sensitivity of the breast cancer cells (HCC1806) to the cytotoxic effects of the chemotherapeutic agent MNNG by suppressing the expression of PARP1.

Entities:  

Keywords:  Alkylating chemotherapeutic agent; Breast cancer; MNNG; MicroRNA-181b; PARP1

Mesh:

Substances:

Year:  2017        PMID: 28660502     DOI: 10.1007/s00404-017-4444-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  3 in total

Review 1.  ChrXq27.3 miRNA cluster functions in cancer development.

Authors:  Kosuke Yoshida; Akira Yokoi; Yusuke Yamamoto; Hiroaki Kajiyama
Journal:  J Exp Clin Cancer Res       Date:  2021-03-25

2.  Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the expression of EGFR isoforms A and D.

Authors:  Shankar Dhamodharan; Mathew Maria Rose; Sundaram Reddy Chakkarappan; Karuppiah Vijayamuthuramalingam Umadharshini; Ramalingam Arulmurugan; Shanmugam Subbiah; Ituro Inoue; Arasambattu Kannan Munirajan
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

Review 3.  MicroRNAs as a clue to overcome breast cancer treatment resistance.

Authors:  Iris Garrido-Cano; Birlipta Pattanayak; Anna Adam-Artigues; Ana Lameirinhas; Sandra Torres-Ruiz; Eduardo Tormo; Raimundo Cervera; Pilar Eroles
Journal:  Cancer Metastasis Rev       Date:  2021-09-15       Impact factor: 9.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.